Clinical trial
Ziprasidone And Olanzapine's Outcomes In Mania
NCT00329108 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Terminated
Key facts
| NCT number | NCT00329108 |
|---|---|
| Title | Ziprasidone And Olanzapine's Outcomes In Mania |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel Group Study, Comparing The Efficacy And Tolerability Of Ziprasidone (Zeldox, Geodon) vs. Olanzapine (Zyprexa) In The Treatment And Maintenance Of Response In Patients With Acute Mania |
| Acronym | ZOOM |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acute Mania, Bipolar Disorder, Manic |
| Intervention type | Drug |
| Interventions | ziprasidone hydrochloride, olanzapine |
| Enrollment | 29 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | May 24, 2006 |
| Last update posted | Mar 29, 2021 |
| Countries | Germany, Greece, Italy, Spain, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: